20.88

7.19% 1.40

After Hours: 21.17 0.29 +1.39%

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $20.88, with a volume of 4.16M. It is up +7.19% in the last 24 hours and up +65.32% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$19.48

Open:

$19.6

24h Volume:

4.16M

Relative Volume:

1.22

Market Cap:

$2.98B

Revenue:

$62.38M

Net Income/Loss:

$-101.59M

P/E Ratio:

-24.16

EPS:

-0.8644

Net Cash Flow:

$-139.93M

1W Performance:

+11.78%

1M Performance:

+65.32%

6M Performance:

+161.98%

1Y Performance:

+1,173%

1-Day Range:

$19.60

$21.82

1-Week Range:

$18.46

$21.82

52-Week Range:

$1.03

$21.82

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

137

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	20.88	2.78B	62.38M	-101.59M	-139.93M	-0.8644
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-23-26	Initiated	Mizuho	Outperform
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

Mar 25, 2026

TNGX: 93,000 shares from option exercise; Adam Crystal prior 10b5-1 sales (TNGX) - Stock Titan

Mar 25, 2026

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.3%Still a Buy? - MarketBeat

Mar 25, 2026

TNGX stock hits record high on inking collaboration deal with ERAS - MSN

Mar 25, 2026

Mar 24, 2026

Tango Therapeutics Ignites: 11% Surge to Historic Highs Signals Biotech Power Play - Bitget

Mar 24, 2026

Tango Therapeutics stock hits all-time high at 19.83 USD By Investing.com - Investing.com Canada

Mar 24, 2026

Mar 23, 2026

Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month HighShould You Buy? - MarketBeat

Mar 23, 2026

Trading Recap: How does Tango Therapeutics Inc correlate with Nasdaq2026 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn

Mar 21, 2026

Wall Street Zen Downgrades Tango Therapeutics (NASDAQ:TNGX) to Sell - MarketBeat

Mar 21, 2026

Tango Therapeutics (TNGX) sees cautious analyst optimism following earnings - MSN

Mar 21, 2026

Mar 20, 2026

Aug Levels: Will Tango Therapeutics Inc benefit from rising consumer demandSwing Trade & Real-Time Sentiment Analysis - baoquankhu1.vn

Mar 20, 2026

TNGX Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 20, 2026

Mar 19, 2026

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - GlobeNewswire Inc.

Mar 19, 2026

TNGX Stock Price, Quote & Chart | TANGO THERAPEUTICS INC (NASDAQ:TNGX) - ChartMill

Mar 19, 2026

Mar 18, 2026

Tango TherapeuticsFinancial Details - Crunchbase

Mar 18, 2026

Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - MSN

Mar 18, 2026

It Takes Two To TangoClinical Progress, Solid Balance Sheet Driving Momentum In TNGX - RTTNews

Mar 18, 2026

Can Tango Therapeutics Inc be recession proofMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Guidance Update: Can Tango Therapeutics Inc sustain earnings growth2026 Institutional Moves & Safe Capital Growth Trade Ideas - baoquankhu1.vn

Mar 17, 2026

Guidance Update: Is Tango Therapeutics Inc undervalued by DCF analysis2026 Earnings Impact & Verified Technical Signals - baoquankhu1.vn

Mar 17, 2026

Tango Therapeutics stock hits 52-week high at $17.64 - Investing.com India

Mar 17, 2026

Tango Therapeutics stock hits 52-week high at $17.64 By Investing.com - Investing.com South Africa

Mar 17, 2026

Mar 16, 2026

Does Tango Therapeutics (TNGX) Trial Pact and ESOP Shelf Hint at a Pivotal Strategic Turn? - simplywall.st

Mar 16, 2026

Tango Therapeutics (NASDAQ:TNGX) Hits New 12-Month HighShould You Buy? - MarketBeat

Mar 16, 2026

Why Tango Therapeutics Stock Is Breaking Out Now - TipRanks

Mar 16, 2026

Farallon Capital Management LLC Buys 1,600,000 Shares of Tango Therapeutics, Inc. $TNGX - MarketBeat

Mar 16, 2026

Mar 14, 2026

Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st

Mar 14, 2026